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ABSTRACT 
Down's syndrome, a chromosomal disorder, results from the fetus 
receiving a triple amount of a band on the long arm of chromosome 21. The 
incidence of Down's syndrome births has decreased, but the prevalence of 
older Down's syndrome individuals has increased. Aging appears to occur 
earlier and progress faster in Down's syndrome than in the general 
population. Unique early aging changes have been found to occur in the 
immune, endocrine and neural systems. Neuropathological changes that 
resemble Alzheimer's disease occur in almost all Down's syndrome 
individuals by age 40. Common ocular problems in Down's syndrome are 
moderate refractive error, esotropia and blepharitis. High myopia, 
keratoconus and nystagmus are more frequent than in the general 
population. 
OCULAR ASSESSMENT OF THE AGING DOWN'S SYNDROME PATIENT 
INTRODUCTION 
Aging is a universal process. This process is variable in normals, but 
in Down's syndrome, individuals undergo some aging changes that are 
uniquely different than normals. They also seem to have a different 
timetable to their aging changes. It is currently felt that aging occurs 
earlier and progresses faster in Down's syndrome. For instance, a 45 year 
old Down's syndrome individual will commonly exhibit aging changes 
normally not present until 65 years of age in normals. Maximum recorded 
life span for a Down's syndrome individual is approximately 71 years old.1 
The health care practitioner must keep in mind specia,l considerations 
when working with the Down's syndrome patient. They are born with a 
genetic alteration which can impact any of the organ systems of the body. 
As Down's syndrome patients increase in age, some unique considerations 
must be kept in mind. As members of the health care team, optometrists 
have a professional obligation to be competent in handling these patients. 
Although Down's syndrome is relatively rare, chances are good that an 
optometrist in every community will be called on to care for a Down's 
syndrome individual. The following material is a review of the important 
Down's syndrome considerations, with a special emphasis on aging. 
1 
f 
i 
I 
I 
I ~ 
2 
HISTORY 
In 1866 Langdon Down was the first to ascribe the unfortunate term 
"mongolism" to those with mental deficiency, short stature and mongolian 
features. 2 •3 He was attempting to use ethnic background as a means of 
categorizing the mentally retarded. Down, himself, questioned his own 
findings because the disease seemed to cross ethnic barriers. At first 
mongolism was frequently confused with cretinism. Subsequently, 
workers differentiated Down's syndrome to be a distinct entity. The first 
documentation of ocular findings for mongolism occurred in 1891 
(Oiiver). 4 It wasn't until 1959 that the true etiology of Down's syndrome 
was advanced with the recognition that those with Down's syndrome have 
47 chromosomes.s 
GENETICS OF DOWN'S SYNDROME 
Down's syndrome is a chromosomal disorder resulting from a triple 
amount of the critical chromosomal band 21 q 22. 6 This band which 
results in the phenotype of Down's syndrome is part of the long arm of 
chromosome 21. Triplication of this critical portion can result from three 
different genetic alterations. 96% of the cases result from complete 
trisomy 21 and is caused by nondisjunction in either parent. The 
chromosome count in this condition is 47. It is one of the few trisomies, 
which is allowed by nature to come to full term. 3% of the cases result 
from unbalanced translocations, usually to the D and G chromosomal 
groups. Chromosome count here is 46 and these cases tend to be familial. 
Mosaics account for about 1% of Down's syndrome. These cases are a 
result of mitotic nondisjunction of chromosome 21 in an early stage of 
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embryogenesis. 7 Their cells contain either 46 or 47 chromosomes. 
Depending on the stage at which embryogenesis was affected, these 
individuals can be either mildly or more severely affected. 
It is estimated that chromosome 21 represents less than 2°/o of the 
human genome of approximately 100,000 genes. a Chromosome 21 is 
estimated to contain less than 1 ,000 genes with the portion 21 q 22, 
itself having an estimate of less than 100 genes. This small gene pool 
which is responsible for the phenotype in Down's syndrome has lead some 
researchers to feel that most of these genes are regulatory involved 
rather than structural. At this time only five genes have been mapped to 
chromosome 21. One of these is for cytoplasmic superoxide dismutase, an 
enzyme which has been known to have a dosage effect in Down's syndrome. 
Some interferon regulation has also been mapped to here.9 
CHARACTERISTICS OF DOWN'S SYNDROME 
There are a number of diagnostic clinical features which are 
commonly found in this syndrome. The unfortunate term "mongolism" 
resulted from the flat facial profile, oblique palpebral fissures and 
epicanthic folds.? Varying skeletal anomalies are present such as short 
limbs, broad and short trunk, broad hands, small nose, depressed nasal 
bridge and dysplastic pelvis. 1 0 Additional signs are muscle hypotonia, 
hyperflexibility, dysplastic ears and transverse palmer crease. Congenital 
heart disease occurs in about 30% of Down's syndrome newborns; usually it 
is a ventricular septal defect. Males are usually sterile; females may be 
fertile. Duodenal atresia is also known to occur. 
The mental retardation occuring in Down's syndrome is felt to be 
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severe to moderate in range with about 80% having an I.Q. between 25 to 
50. 7 Studies have shown that the introduction of special developmental 
programs. can increase intellectual abilities in a portion of the Down's 
syndrome population_11 
INCIDENCE AND PREVALENCE OF DOWN'S SYNDROME 
The incidence of Down's syndrome is strongly influenced by maternal 
age. 8 The risk of bearing a child with Down's syndrome is 1 in 2,000 at 
age 20 years. The risk rises gradually until at age 35 where the risk 
increases to 1 in 300. By age 45 years, the risk has risen to 1 in 45. The 
cause of the mitotic nondisjunction in the ova is not presently know, but 
since the ova are present from birth, environmental factors may influence 
this.? Recent studies have shown that in 20% of the cases the extra 
chromosome is from the father. No conclusions have yet been reached 
concerning whether paternal age has an influence on the incidence of 
Down's syndrome. 
Maternal bearing age and use of prenatal diagnosis seem to be the two 
primary factors influencing the crude incidence of Down's syndrome births. 
Between the years of 1960 and 1978 these was a substantial decrease in 
Down's syndrome births. Crude incidence shifted from 1 .33/1 ,000 births 
in 1960 to .99/1 ,000 births in 1978.1 2 It is felt that most of this 
decrease was due to a 50 percent reduction of women 35 years of age and 
over giving birth. Decreased maternal bearing age and reduction in the 
total number of births in the United States accounted for most of this 
change. Maternal bearing age distributions changed by the year 1978 such 
that women over 35 accounted for only 20% of all Down's syndrome 
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births. 13 
In 1970 the medical community felt that it was economically 
justifiable to try to make prenatal diagnosis available to all mothers older 
than age 35. The rational behind this, at this time, was that women 35 
years and older had only 13% of all pregnancies, but delivered 50% of all 
Down's syndrome births. 1 3 Prenatal diagnosis involves the removal of 
amniotic fluid from the mother after the twelfth week of pregnancy.14 
Usually it is cells from the fetal skin which are analyzed. It is estimated 
that for each 10% increase in the utilization rate of prenatal diagnosis by 
mothers over the age of 35, one can expect a 3.5% drop in the overall 
Down's syndrome live birth rate. 15 Risks of prenatal diagnosis are low 
being between 1 and .3%.13 Usual complications are vaginal bleeding and 
amniotic fluid leakage. Current usage by women over age 35 is at about 
17%. 
Given current prenatal diagnosis rates, projections for the future 
predict an increase in Down's syndrome births from 4,300 in 1979 to 
5,300 in 1990.16 The reason for this projected increase is that the age 35 
to 49 category will rise from a 1980 level of 19 million to about 30 
million by 1995. Another factor may be the trend towards increased mean 
maternal child bearing age. 
There has been a marked increase in the prevalence of older Down's 
syndrome patients during the past decade. 1 7 There are a number of 
reasons for their increased survival. Increased effort, interest and 
technology have improved the one year survival rate from an estimate of 
50% prior to the year 1950 to about 94% in 1984. Improved surgical 
techniques have reduced the one year mortality ratio for congenital heart 
disease patients to less than 13%. It is now felt that 82.4% of Down's 
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syndrome children survive the first 10 years of life.1 8 
Quality of life has improved significantly for the Down's syndrome 
individual. Significant improvements have been made in the diagnostic, 
therapeutic and educational skills necessary to help these individuals.17 
An important improvement has been the recent trend towards 
deinstitutionalization. This has resulted in increased stimulation and 
mobility, earlier intervention into the problems inherent with Down's 
syndrome and more careful attention to diet and fitness. Reliable 
life-tables indicate that it is not unusual for Down's syndrome people to 
reach 44, with 60+ not being exceptional. 
AGING CHANGES IN DOWN'S SYNDROME 
In the past there have been many citations in the literature indicating 
that people with Down's syndrome tend to age prematurely. The aging 
process is also felt to progress faster than in the general population. The 
recent increase in longevity of the Down's syndrome patient has resulted 
in renewed interest in this area. 
Researchers have found a variety of evidence to support the 
premature aging theory. Down's persons tend to appear older than their 
actual age. 9 This is due to premature greyness, absence of hair and 
dryness of the skin.1 9 • 2 0 In one study aortic and pulmonary valve 
funestrations were found in 50% of a Down's syndrome group as compared 
to only 4% of the controls.21 Cataracts tend to form earlier in the lens of 
Down's patients.22 The skeletal system tends to show some rapid aging 
changes. 23· 24 Postural changes that usually appear in the fifth or sixth 
decade of life have been found in the third decade.25 Early menopause and 
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testicular atrophy have also been found.26 
An increase in the oxidative enzyme superoxide dismutase (SOD) has 
been dosage linked to Down's syndrome.23 This enzyme has been 
genetically mapped to the long arm of chromosome 21. It is responsible 
for the oxidative process with the cell ultimately resulting in the hydroxyl 
radical. Excess dosage of SOD may lead to cell damage and thus be a part 
of the aging process. 
For a long time, the immune status of Down's syndrome patients has 
been under investigation. Respiratory infections are 1 00 times more 
common in Down's syndrome children as compared to age matched 
contra Is. 27 Down's individuals have a high frequency of malignancies, 
especially leukemia which is 20 times the normal rate.28 •29 There is also 
an increased prevalence of anti-thyroid antibodies.30 Mortality from 
infectious disease is high.3 1 Down's syndrome has also been associated 
with a high incidence of chronic carrier state for Australian antigen. 
Immunodeficiency seems to be an integral feature of Down's 
syndrome. There have been reports of slight 8-cell system irregularities, 
but the preponderance of current evidence seems to point towards the 
T-cell system. 29 It appears that changes occur in the thymic epithelial 
cells which results in a failure to secrete the necessary hormones to 
stimulate T-cell differentiation. Histologic changes noted in the Down's 
syndrome thymus include lymphocyte depletion, diminution of the cortex 
of the lobules and degeneration of the Hassall corpuscles.27 Newborns 
with Down's syndrome already have present a degeneration of the Hassall 
corpuscles which are felt to be a morphologic Index of the function of 
thymic epithelial cells. Lymphocyte depletion has been noted in the T-cell 
zones of the spleens and lymph glands of Down's syndrome patients. 
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Failure of T -cell differentiation may be a key factor in the early 
appearance of autoantibodies in Down's syndrome.3 1 They may also play a 
role in the lymphoid malignancies. The recurrent infections common in 
Down's syndrome may stress an already deficient immune system and thus 
tend to exhaust the system. Institutionalization with its high rate of 
recurrent infections, would be an important accelerating factor if this 
were true. 
There is an increased prevalence of thyroid disorder in Down's 
syndrome, but studies concerning thyroid function have been conflicting. 
One study found an overall prevalence of thyroid dysfunction to be 
19 .5%. 32 In this study hypothyroidism was found in 17%, hyperthyroidism 
in 2.5°/o and 18% of the patients had goiter. Thyroid antibodies were found 
in 33% of the subjects. Most of the abnormal thyroid function was shown 
to be in adolescents and young adults. 
A number of neurological changes are characteristic for the aging 
Down's syndrome patient.9 There have been reports of age related changes 
in the EEG. An increased frequency of late onset epilepsy has been noted. 
The visual, auditory and somatosensory evoked responses have a larger 
late wave component in Down's syndrome as compared to normal.33 ,34 
Thus Down's syndrome subjects can be characterized as lacking central 
inhibitory components. Usually in normals the late wave components 
decrease with aging, but this change does not occur in Down's syndrome. 
The neurological change of most interest today is the Alzheimer's 
disease-like dementia which frequently occurs in many older Down's 
syndrome patients. The first notation of a dementia occurring in Down's 
syndrome occured over 1 00 years ago. In recent years a vast amount of 
research has attempted to establish a relationship between Alzheimer's 
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disease and Down's syndrome. 
Alzheimer's disease is a form of dementia that is felt to affect over 
two million Americans.35 More than 60 disorders can cause the symptom 
complex, termed dementia. Alzheimer's disease accounts for 50 to 60% of 
these cases. This condition is considered to be age dependent with 
incidence rising markedly in the 75 to 85 age group. 
Presently there is no peripheral biochemical marker known for 
Alzheimer's disease. 36 A cerebral biopsy must be performed in order to 
obtain a definitive diagnosis. The principle morphological changes in the 
brain are cortical atrophy, loss of neurons and the presence of 
neurofibrillary tangles, neuritic plaques and amyloid deposits. 
Neurofibrillary tangles are abnormal neurons whose cytoplasm is filled 
with microscopic helically wound filamentary structures. Neuritic 
plaques are clusters of degenerating nerve terminals. There is felt to be a 
correlation between the number of these lesions and the degree of the 
dementia. The neurotransmitters felt to be most lacking in Alzheimer's 
disease is acetylcholine and choline acetyltransferase. Known risk 
factors for the disease are age, history of serious head trauma, occurrence 
in a parent of sibling and presence of trisomy 21. Researchers are 
uncertain whether Alzheimer's disease is a biochemical deficiency, an 
infectious process, a toxic condition or an acceleration of normal aging.35 
The dementia that occurs in Down's syndrome usually is not present 
before age 40 years. By age 40 nearly 1 00% of the Down's syndrome 
population have the neuropathologic plaques and tangles that are 
characteristic of Alzheimer's disease, 37 -41 but only 25 to 40% become 
demented. 41 There is some evidence that Down's syndrome individuals 
invariably experience declining mental abilities as they age. Older Down's 
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patients in general tend to perform poorer on tests of attention, visual 
memory and intelligence. The dementia which occurs in older Down's 
patients is characterized by changes in behavior, loss of self care skills 
and deterioration in the use and understanding of language. Affected 
Down's syndrome brains show a reported reduction in the enzymes choline 
acetyltransferase and acetylcholine esterase.3 7 Dementia is not 
inevitable for all aging Down's patients, but a considerable number do have 
this problem. 
A number of interesting models have been advanced in an attempt to 
establish a relationship between Alzheimer's disease and Down's 
syndrome. Mozer, et. a135 suspect that Down's syndrome is a congenital 
form of Alzheimer's disease and that both conditions are the result of a 
ubiquitous infective pathogen that affects genetically susceptible 
individuals. An atypical virus may be present in a parent which would 
result in the nondisjunction causing Down's syndrome. The virus would 
then persist in the fetus and eventually lead to Alzheimer's disease in 
long-time survivors. No virus has as yet been isolated for Alzheimer's 
disease, but Alzheimer's disease does have similarities to the 
transmissible encephalopathies. 
Schweber6 has suggested a unitary genetic hypothesis for 
Alzheimer's disease and Down's syndrome. This theory holds that 
Alzheimer's disease and Down's syndrome form a continuum. The theory 
here is that Alzheimer's disease results from a tripling of a subsection of 
the critical segment (21 q 22) which is responsible for the phenotype in 
Down's syndrome. Support for this theory lies in the fact that Down's 
syndrome is more common in families of Alzheimer's patients. 
OCULAR FEATURES OF DOWN'S SYNDROME 
The mentally retarded tend to have a higher frequency of ocular 
anomalies than the general population.42 •43 Down's patients also tend to 
have a high frequency of ocular anomalies, but they also tend to have some 
uniquely different presentations. 
External ocular findings that are commonly found in Down's syndrome 
are epicanthus, oblique upward and outward slanting palpebral fissures, 
and narrowed interpupillary distance. Jaeger3 found epicanthus in 17.3% 
whereas Gaynon and Schimek44 found it to be present in 53%. Variability 
in estimates of epicanthus may result from lack of a common definition. 
Also, some researchers feel that epicanthus prevalence may diminish by 
adolescence. 45 The palpebral aperatures in Down's syndrome tend to be 
oblique and short. Lowe46 found the orbital axes to be inclined at 75 
degrees as compared to the norm of 45 degrees. During growth the 
increase in interpupillary distance may lag behind the changes in skull 
breadth. 4 7 This results in the eyes appearing set abnormally close 
together. 
Refractive error tends to be significant in Down's syndrome. Jaeger3 
used a criteria level of refractive error (~ ± 4.00 diopters of sphere or 
-2.50 diopters of cylinder) to judge his Down's syndrome subjects. 53.5% 
of them exceeded this level and the refractive error seemed to be evenly 
distributed between myopia, hyperopia and astigmatism. Using a different 
criteria level of (> ± 8.00 diopters of sphere or -5.00 diopters of cylinder) 
16.9% of the Down's subjects exceeded this level. Myopia was the 
predominant refractive error in this category. Other studies have also 
found a significant amount of high myopia to be present in Down's 
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syndrome. 48 •49 
Strabismus is commonly found in Down's syndrome. Estimates of the 
amount of strabismus range between 3246 to 41.3 %3 with esotropia being 
the predominant form. Hiles et. alSO found 34% of their patients to be 
strabismic with 28% being esotropes. About half of the esotropes were 
felt to be accommodative esotropes. 
Keratoconus is felt to have an incidence in Down's syndrome of about 
5.5 to 8%.51 There have been many reports of acute hydrops occurring in 
patients with Down's syndrome. 52-5 4 Acute hydrops is rare in normal 
keratoconus patients. Eye rubbing or trauma may be associated with this. 
Cullen found acute keratoconus to be one of the leading causes of blindness 
in Down's syndrome.55•56 
Lens opacities in Down's syndrome tend to occur earlier than in the 
general population and they also tend to be progressive.3 Lens opacities 
are rare in Down's syndrome children, but they have a dramatic rise in 
frequency after puberty. It is difficult to compare various studies of lens 
opacities in Down's syndrome because the descriptive terminology varies 
so much. Estimates of incidence of lens opacities range between 25 to 
60°/o. Jaeger found 55.4% of his Down's syndrome subjects to have lens 
opacities. 36.5% of the subjects had flake-like opacities with the average 
age of presentation being 36 years. 18.9% of the patients had senile 
cataracts with average age of presentation being 48. 
Early failure of accommodative ability in Down's syndrome children 
has been cited in one preliminary report.57 This was the only reference to 
this problem that was found in the literature. Further work needs to be 
done in order to explore this possible problem. No mention was made in 
this study of the type of drugs that these children were taking. 
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Considering the many health problems of Down's syndrome children and the 
large number of drugs which affect accommodative ability, this factor 
should be considered. 
Nystagmus has been noted in Down's syndrome. Study incidences 
noted were 9%48 and 16%.49 
Bleparitis has a high incidence of occurrence in Down's syndrome. 
Estimates of 4648 and 38%49 have been made. 
In Down's syndrome the ocular anomalies which occur tend to be 
composed of a variety of hyperplasias, hypoplasias, hamartomata, tissue 
defects and heterotopias.58 •59 All tissues except the vitreous have been 
shown to exhibit these various abnormalities. Most of the variations from 
normal are minor, and no variation has been found that does not 
occasionally occur in the general population. Thus, there is no "Down's 
Syndrome Eye." Hypoplasias and small tissue defects tend to be found in 
Descemet's membrane, corneal endothelium, iris stroma and retinal 
pigment epithelium. Heterotopias tend to occur in the lacrimal gland and 
iris pigment epithelium. Hyperplasias or hamartomata have been found in 
the conjunctiva, cornea, sclera, uvea and retina. 
The iris in Down's syndrome can be characterized by Brushfield spots, 
peripheral iris stromal thinning, and a tendency towards blue or grey 
irides. Donaldson60 reported Brushfield spots in 85% and peripheral 
stromal thinning in 81% of his Down's syndrome patients. Brushfield spots 
are peripheral iris speckles which are felt to be made up of aggregates of 
stromal fibers. They are .1 to 1 mm in size and tend to have areas of 
decreased stromal fibers surrounding them.6 1 Shapiro and France48 found 
blue or grey irides in 87% of their Down's syndrome subjects. 
The fundus in Down's syndrome individuals is felt to have similar 
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coloration to that of a blond. 6 2 Despite refractive error or skin 
coloration, a decrease in pigmentation is noted in the Down's syndrome 
fundus. The fovea tends to be light colored and indistinct. The disc tends 
to appear rosy and it has been determined that an increased number of 
vessels leave it. 6 3 It is common to see peripapillary and pigment 
epithelial cell atrophy. Peripheral cystoid degeneration is common. 
Characteristic fundus patterns occur in those with high myopia. Retinal 
detachments are felt to be more common in Down's syndrome. This may be 
due to the increased trauma which may commonly occur in their lifestyle. 
CONCLUSION 
The mental retardation in Down's syndrome has been described as 
being severe to moderate in range. Special educators have found that 
environmental improvements can result in substantial increases in the 
performance level of these patients. By providing quality vision care to 
individuals with Down's syndrome, optometrists can do a lot to enhance 
their lifestyle. These individuals will be special patients. They will 
require an understanding of their many disabilities. Special 
considerations will have to be kept in mind, such as their uniquely 
different aging process. The improvement made may be small, but, 
professionally, it can be very satisfying to help enhance the already 
limited lifestyle of the mentally disabled. 
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